[O-33] Oral Session 33
Neuroimaging・Clinical trial　etc

[O-33-6] SUNFISH Part 2: Efficacy and safety of risdiplam in patients with Type 2 or non-ambulant Type 3 SMA

^○Kayoko Saito¹, Eugenio Mercuri², Nina Barisic³, Anna Kostera-pruszczyk⁴, Riccardo Masson⁵, Elena Mazzone², Andres Nascimento⁶, Carole Vuillerot⁷, Sabine Fuerst-recktenwald⁸, Marianne Gerber⁸, Ksenija Gorni⁸, Heidemarie Kletzl⁸, Wai Yin Yeung⁹, John W. Day¹⁰ (1.Institute of Medical Genetics, Tokyo Women's Medical University, 2.Paediatric Neurology and Nemo Center, Catholic University and Policlinico Gemelli, 3.Clinical Medical Center Zagreb, University of Zagreb Medical School, Department of Paediatrics, 4.Katedra I Klinika Neurologii Warszawskiego Uniwersytetu, 5.Carlo Besta Neurological Research Institute Foundation, Developmental Neurology Unit, 6.Neuromuscular UnLit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Deu, CIBERER - ISC III, 7.Department of Pediatric Physical Medicine and Rehabilitation, Hôpital Mère Enfant, CHU-Lyon, 8.F. Hoffmann-La Roche Ltd., 9.Roche Products Ltd., 10.Department of Neurology, Stanford University)